Bruton’s tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are current standard of care for patients with EGFR mutation and metastatic non-small-cell lung carcinoma (NSCLC), but most patients using EGFR TKIs acquire resistance later. So, overcoming resistance of EGFR TKIs has become a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Chi-Tai, Chen, Tzu-Tao, Satriyo, Pamungkas Bagus, Wang, Chun-Hua, Wu, Alexander T. H., Chao, Tsu-Yi, Lee, Kang-Yun, Hsiao, Michael, Wang, Liang-Shun, Kuo, Kuang-Tai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316404/
https://www.ncbi.nlm.nih.gov/pubmed/34315851
http://dx.doi.org/10.1038/s41389-021-00345-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316404/
https://www.ncbi.nlm.nih.gov/pubmed/34315851
http://dx.doi.org/10.1038/s41389-021-00345-8

Ejemplares similares